**Recent U.S. IPO activity, including multiple October 2026 pricings such as TRex Bio and Retension Pharmaceuticals alongside filings for Iambic Therapeutics and others, underscores an active window well before 2027.** Q3 saw $34 billion raised by operating companies—exceeding prior full-year totals—with Nasdaq IPO Pulse data showing supportive conditions persisting into early 2027 despite a September softening. Record YTD proceeds of $146 billion reflect strong investor appetite for select growth names, even as larger AI-related deals like Anthropic face potential timing shifts. Traders price high implied probability for additional listings through year-end, driven by earnings momentum, sector trends in biotech and infrastructure, and a pipeline of confidential filings. Key near-term catalysts include mid-October launches and any regulatory or market volatility that could influence deal timing.